Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial.

Marks WH, Mamode N, Montgomery R, Stegall MD, Ratner LE, Cornell LD, Rowshani AT, Colvin RB, Dain B, Boice JA, Glotz D; C10-001 study group.

Am J Transplant. 2019 Mar 19. doi: 10.1111/ajt.15364. [Epub ahead of print]

PMID:
30887675
2.

Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival.

Aubert O, Higgins S, Bouatou Y, Yoo D, Raynaud M, Viglietti D, Rabant M, Hidalgo L, Glotz D, Legendre C, Delahousse M, Shah N, Sis B, Campbell P, Mengel M, Jouven X, Duong Van Huyen JP, Lefaucheur C, Loupy A.

J Am Soc Nephrol. 2019 Mar 14. pii: ASN.2018070777. doi: 10.1681/ASN.2018070777. [Epub ahead of print]

PMID:
30872323
3.

Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.

Bouatou Y, Viglietti D, Pievani D, Louis K, Duong Van Huyen JP, Rabant M, Aubert O, Taupin JL, Glotz D, Legendre C, Loupy A, Lefaucheur C.

Am J Transplant. 2019 Feb 12. doi: 10.1111/ajt.15299. [Epub ahead of print]

PMID:
30748089
4.

Lack of impact of pre-emptive deceased-donor kidney transplantation on graft outcomes: a propensity score-based study.

Foucher Y, Le Borgne F, Legendre C, Morelon E, Buron F, Girerd S, Ladrière M, Mourad G, Garrigue V, Glotz D, Lefaucheur C, Cassuto E, Albano L, Giral M.

Nephrol Dial Transplant. 2018 Oct 15. doi: 10.1093/ndt/gfy317. [Epub ahead of print]

PMID:
30325453
5.

Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.

Parlati L, Sirmai L, Dupuy CA, Glotz D, Pol S.

Clin Res Hepatol Gastroenterol. 2018 Oct 4. pii: S2210-7401(18)30183-9. doi: 10.1016/j.clinre.2018.09.002. [Epub ahead of print] No abstract available.

PMID:
30293896
6.

Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review.

Charpentier C, Delyon J, Glotz D, Peraldi MN, Rerolle JP, Barrou B, Ducroux E, Coilly A, Legeai C, Barete S, Lebbé C.

Transplantation. 2019 Jan;103(1):e22-e28. doi: 10.1097/TP.0000000000002468.

PMID:
30273235
7.

Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.

Zehou O, Leibler C, Arnault JP, Sayegh J, Montaudié H, Rémy P, Glotz D, Cordonnier C, Martin L, Lebbé C.

Am J Transplant. 2018 Dec;18(12):3065-3071. doi: 10.1111/ajt.15071. Epub 2018 Sep 21.

PMID:
30107088
8.

Correction: Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 Jul 27;15(7):e1002637. doi: 10.1371/journal.pmed.1002637. eCollection 2018 Jul.

9.

Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.

Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, Legendre C, Taupin JL, Zeevi A, Loupy A, Lefaucheur C.

Kidney Int. 2018 Oct;94(4):773-787. doi: 10.1016/j.kint.2018.03.015. Epub 2018 May 22.

PMID:
29801667
10.

Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 May 25;15(5):e1002572. doi: 10.1371/journal.pmed.1002572. eCollection 2018 May. Erratum in: PLoS Med. 2018 Jul 27;15(7):e1002637.

11.

Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report.

Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, Mannon RB, Reed EF, Tinckam K, Askar M, Chandraker A, Chang PP, Colvin M, Demetris AJ, Diamond JM, Dipchand AI, Fairchild RL, Ford ML, Friedewald J, Gill RG, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine DJ, Levitsky J, Mengel M, Milford E, Newell KA, O'Leary JG, Palmer S, Randhawa P, Smith J, Snyder L, Starling RC, Sweet S, Taner T, Taylor CJ, Woodle S, Zeevi A, Nickerson P.

Am J Transplant. 2018 Jul;18(7):1604-1614. doi: 10.1111/ajt.14752. Epub 2018 May 22.

PMID:
29603613
12.

The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice.

Cross AR, Glotz D, Mooney N.

Front Immunol. 2018 Jan 29;9:106. doi: 10.3389/fimmu.2018.00106. eCollection 2018. Review.

13.

Intravenous Immunoglobulins in the Prevention of Rejection of a Second or Third Kidney Graft.

Glotz D, Rostaing L, Merville P, Squifflet JP, Lebranchu Y.

Transplant Proc. 2018 Jan - Feb;50(1):70-71. doi: 10.1016/j.transproceed.2017.11.010.

PMID:
29407334
14.

Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin.

Lion J, Burbach M, Cross A, Poussin K, Taflin C, Kaveri S, Haziot A, Glotz D, Mooney N.

Front Immunol. 2017 Dec 14;8:1761. doi: 10.3389/fimmu.2017.01761. eCollection 2017.

15.

Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C.

J Am Soc Nephrol. 2018 Feb;29(2):606-619. doi: 10.1681/ASN.2017070749. Epub 2017 Dec 18.

16.

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, van Huyen JPD, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M.

Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.

17.

T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.

Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, Louis K, Glotz D, Legendre C, Duong Van Huyen JP, Loupy A.

Am J Transplant. 2018 Feb;18(2):377-390. doi: 10.1111/ajt.14565. Epub 2017 Nov 21.

18.

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.

J Am Soc Nephrol. 2018 Feb;29(2):620-635. doi: 10.1681/ASN.2017050589. Epub 2017 Oct 17.

19.

Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies.

Tambur AR, Audry B, Antoine C, Suberbielle C, Glotz D, Jacquelinet C.

Am J Transplant. 2017 Dec;17(12):3149-3158. doi: 10.1111/ajt.14389. Epub 2017 Jul 17.

20.

Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.

Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, Legendre C, Taupin JL, Duong Van-Huyen JP, Loupy A, Lefaucheur C.

Kidney Int. 2017 Sep;92(3):729-742. doi: 10.1016/j.kint.2017.03.033. Epub 2017 May 26.

PMID:
28554738
21.

Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF.

J Am Soc Nephrol. 2017 Jun;28(6):1912-1923. doi: 10.1681/ASN.2016070797. Epub 2017 Mar 2.

22.

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.

Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, Nankivell BJ, Colvin RB, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell L, Drachenberg C, Dragun D, de Kort H, Gibson IW, Kraus ES, Lefaucheur C, Legendre C, Liapis H, Muthukumar T, Nickeleit V, Orandi B, Park W, Rabant M, Randhawa P, Reed EF, Roufosse C, Seshan SV, Sis B, Singh HK, Schinstock C, Tambur A, Zeevi A, Mengel M.

Am J Transplant. 2017 Jan;17(1):28-41. doi: 10.1111/ajt.14107.

23.

Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, Lefaucheur C.

J Am Soc Nephrol. 2017 Feb;28(2):702-715. doi: 10.1681/ASN.2016030368. Epub 2016 Aug 4.

24.

The blurring frontier between autoimmunity and alloimmunity.

Glotz D.

Curr Opin Organ Transplant. 2016 Aug;21(4):349. doi: 10.1097/MOT.0000000000000339. No abstract available.

PMID:
27348474
25.

Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation.

Viglietti D, Lefaucheur C, Glotz D.

Curr Opin Organ Transplant. 2016 Aug;21(4):433-40. doi: 10.1097/MOT.0000000000000324. Review.

PMID:
27348472
26.

Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?

Tambur AR, Glotz D, Herrera ND, Chatroop EN, Roitberg T, Friedewald JJ, Gjertson D.

Hum Immunol. 2016 Aug;77(8):624-630. doi: 10.1016/j.humimm.2016.05.025. Epub 2016 Jun 3.

PMID:
27267046
27.

Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs.

Cross AR, Lion J, Loiseau P, Charron D, Taupin JL, Glotz D, Mooney N.

Hum Immunol. 2016 Nov;77(11):1092-1100. doi: 10.1016/j.humimm.2016.04.003. Epub 2016 Apr 6. Review.

PMID:
27060781
28.

Delayed Graft Function in Living-Donor Kidney Transplant: A Middle Eastern Perspective.

Al Otaibi T, Ahmadpoor P, Allawi AA, Habhab WT, Khatami MR, Nafar M, Glotz D.

Exp Clin Transplant. 2016 Feb;14(1):1-11. Review.

29.

Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer.

Peraldi MN, Berrou J, Venot M, Chardiny V, Durrbach A, Vieillard V, Debré P, Charron D, Suberbielle C, Chevret S, Glotz D, Dulphy N, Toubert A.

Transplantation. 2015 Nov;99(11):2422-30.

PMID:
26798861
30.

Prospective, multicenter, controlled study of quality of life, psychological adjustment process and medical outcomes of patients receiving a preemptive kidney transplant compared to a similar population of recipients after a dialysis period of less than three years--The PreKit-QoL study protocol.

Sébille V, Hardouin JB, Giral M, Bonnaud-Antignac A, Tessier P, Papuchon E, Jobert A, Faurel-Paul E, Gentile S, Cassuto E, Morélon E, Rostaing L, Glotz D, Sberro-Soussan R, Foucher Y, Meurette A.

BMC Nephrol. 2016 Jan 19;17:11. doi: 10.1186/s12882-016-0225-7.

31.

C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.

Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, Glotz D, Lefaucheur C.

Am J Transplant. 2016 May;16(5):1596-603. doi: 10.1111/ajt.13663. Epub 2016 Mar 3.

32.

HLA Class II Antibody Activation of Endothelial Cells Promotes Th17 and Disrupts Regulatory T Lymphocyte Expansion.

Lion J, Taflin C, Cross AR, Robledo-Sarmiento M, Mariotto E, Savenay A, Carmagnat M, Suberbielle C, Charron D, Haziot A, Glotz D, Mooney N.

Am J Transplant. 2016 May;16(5):1408-20. doi: 10.1111/ajt.13644. Epub 2016 Feb 17.

33.

[Renal transplantation from ABO incompatible donors].

Abboud I, Peraldi MN, Glotz D.

J Med Liban. 2015 Jul-Sep;63(3):159-63. French.

PMID:
26591197
34.

IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.

Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen JP, Vernerey D, Aubert O, Verine J, Jouven X, Legendre C, Glotz D, Loupy A, Zeevi A.

J Am Soc Nephrol. 2016 Jan;27(1):293-304. doi: 10.1681/ASN.2014111120. Epub 2015 Aug 20.

35.

Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.

Aubert O, Kamar N, Vernerey D, Viglietti D, Martinez F, Duong-Van-Huyen JP, Eladari D, Empana JP, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A.

BMJ. 2015 Jul 31;351:h3557. doi: 10.1136/bmj.h3557.

36.

Stratifying Patients Based on Epitope Mismatching: Ready for Primetime?

Glotz D, Tambur A.

Am J Transplant. 2015 Aug;15(8):2021-2. doi: 10.1111/ajt.13343. Epub 2015 Jun 11. No abstract available.

37.

Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies.

Loupy A, Vernerey D, Viglietti D, Aubert O, Duong Van Huyen JP, Empana JP, Bruneval P, Glotz D, Legendre C, Jouven X, Lefaucheur C.

Circ Res. 2015 Aug 14;117(5):470-82. doi: 10.1161/CIRCRESAHA.117.306340. Epub 2015 Jun 8.

PMID:
26056252
38.

Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information.

Tambur AR, Herrera ND, Haarberg KM, Cusick MF, Gordon RA, Leventhal JR, Friedewald JJ, Glotz D.

Am J Transplant. 2015 Sep;15(9):2421-30. doi: 10.1111/ajt.13295. Epub 2015 Apr 30.

39.

Dual Invasive Infection with Phaeoacremonium parasiticum and Paraconiothyrium cyclothyrioides in a Renal Transplant Recipient: Case Report and Comprehensive Review of the Literature of Phaeoacremonium Phaeohyphomycosis.

Colombier MA, Alanio A, Denis B, Melica G, Garcia-Hermoso D, Levy B, Peraldi MN, Glotz D, Bretagne S, Gallien S.

J Clin Microbiol. 2015 Jul;53(7):2084-94. doi: 10.1128/JCM.00295-15. Epub 2015 Apr 22. Review.

40.

Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.

Loupy A, Vernerey D, Tinel C, Aubert O, Duong van Huyen JP, Rabant M, Verine J, Nochy D, Empana JP, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C.

J Am Soc Nephrol. 2015 Jul;26(7):1721-31. doi: 10.1681/ASN.2014040399. Epub 2015 Jan 2.

41.

7th International Immunoglobulin Conference: Transplantation.

Jordan SC, Glotz D.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:64. doi: 10.1111/cei.12514.

42.

7th International Immunoglobulin Conference: Transplantation.

Jordan SC, Glotz D.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:46-7. doi: 10.1111/cei.12507.

43.

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.

Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekberg H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA.

BMJ. 2014 Nov 24;349:g6679. doi: 10.1136/bmj.g6679. Review. Erratum in: BMJ. 2014;349:g7543.

44.

Kidney allograft fibrosis after transplantation from uncontrolled circulatory death donors.

Viglietti D, Abboud I, Hill G, Vernerey D, Nochy D, Antoine C, Fieux F, Assayag M, Verine J, Gaudez F, Loupy A, Glotz D, Lefaucheur C.

Transplantation. 2015 Feb;99(2):409-15. doi: 10.1097/TP.0000000000000228.

PMID:
25222117
45.

New insights in antibody-mediated rejection.

Gosset C, Lefaucheur C, Glotz D.

Curr Opin Nephrol Hypertens. 2014 Nov;23(6):597-604. doi: 10.1097/MNH.0000000000000069. Review.

PMID:
25211610
46.

Epitope analysis of HLA-DQ antigens: what does the antibody see?

Tambur AR, Rosati J, Roitberg S, Glotz D, Friedewald JJ, Leventhal JR.

Transplantation. 2014 Jul 27;98(2):157-66. doi: 10.1097/TP.0000000000000220.

PMID:
25003284
47.

Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection.

Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF.

J Am Soc Nephrol. 2014 Oct;25(10):2267-77. doi: 10.1681/ASN.2013111149. Epub 2014 Apr 3.

48.

Acute enteritis associated with Coxsackievirus A19 in a kidney transplant patient.

Melica G, Langlois AL, Le Goff J, Viglietti D, Glotz D, Molina JM, Peraldi MN.

Transpl Infect Dis. 2014 Apr;16(2):344-6. doi: 10.1111/tid.12191. Epub 2014 Mar 17.

PMID:
24628788
49.

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee.

Am J Transplant. 2014 Feb;14(2):272-83. doi: 10.1111/ajt.12590. Erratum in: Am J Transplant. 2015 Oct;15(10):2784. Rangel, Erika [corrected to Rangel, Erika B].

50.

Complement-binding anti-HLA antibodies and kidney-allograft survival.

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X.

N Engl J Med. 2013 Sep 26;369(13):1215-26. doi: 10.1056/NEJMoa1302506.

Supplemental Content

Support Center